Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?

Access

info:eu-repo/semantics/closedAccess

Date

2019

Author

Kocatürk, Emek
Bülbül Başkan, Emel
Engin, Betül Hacer
Özdemir, Mehmet Akif
Küçük, Özlem Su
Can, Pelin
Örnek, Seçil
Hasal, Eda
Atakan, Nilgün

Metadata

Show full item record

Citation

Kocatürk, E., Bülbül Başkan, E., Engin, B. H., Özdemir, M. A., Küçük, Ö. S., Can, P. ... Atakan, N. (2019). Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment? Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) içinde (484-485. ss.). Lisbon, Portugal, June 01-05, 2019.

Abstract

...

WoS Q Kategorisi

Q1

Source

Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)

Volume

74

Issue

Supplement: 106

URI

https://hdl.handle.net/20.500.12511/5029

Collections